Las citoquinas en el absceso hepático amebiano: un ejemplo de investigación inmunología en el ámbito clínico

Contenido principal del artículo

Autores

Claudia Andrea Cruz Baquero
César Augusto Cruz Baquero

Resumen

El propósito de esta revisión es resaltar la importancia de la investigación en el área de la inmunología y su aplicación en el ámbito clínico. En una primera parte se presentan los descubrimientos más importantes que ayudaron a dilucidar los principales procesos fisiológicos involucrados en las enfermedades y de esta manera ayudaron a redireccionar la investigación en el área de la inmunología. Seguido, se describe un ejemplo de investigación básica relacionada con el papel de las citocinas en el absceso hepático amebiano, mostrando el trabajo de varios grupos de investigación en el mundo, con el objetivo de entender la respuesta inmune contra el parásito. Lo anterior nos permite argumentar la relevancia que tiene la investigación inmunológica dentro del contexto clínico.

Palabras clave:

Detalles del artículo

Licencia

Licencia Creative Commons
NOVA por http://www.unicolmayor.edu.co/publicaciones/index.php/nova se distribuye bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

Así mismo,  los autores mantienen sus derechos de propiedad intelectual sobre los artículos.  

Referencias

1. Cohn M 1. Learning from a contemporary history of immunology. Immunologic Research. June 2017, Volume 65, Issue 3, pp 573–591.
2. Sofia MA, Rubin DT . The Impact of Therapeutic Antibodies on the Management of Digestive Disea- ses: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 Apr;62(4):833-842. doi: 10.1007/ s10620-017-4479-0.
3. Dustin ML, Baldari CT . The Immune Synapse: Past, Present, and Future. Methods Mol Biol. 2017; 1584:1-5. doi: 10.1007/978-1-4939-6881-7_1.
4. Ishii M. Immunology proves a great success for trea-ting systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23. Br J Pharmacol. 2017 Jul;174(13):1875-1880. doi: 10.1111/bph.13784. Epub 2017 Apr 24.
5. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going? Transplant Rev (Orlando). 2017 Jan;31(1):10-17. doi: 10.1016/j.trre.2016.10.006. Epub 2016 Oct 11.
6. Tsutsumi V, Shibayama M. Experimental amebiasis: a selected review of some in vivo models. Arch Med Res 2006; 37: 210 – 220 (Review).
7. Tsutsumi V, Mena-Lopez R, Anaya-Velazquez F, Mar- tínez-Palomo A. Cellular bases of experimental ame- bic liver abscess formation. Am J Pathol 1984; 117: 81– 91
8. Tsutsumi V, Martínez-Palomo A. Inflammatory re- action in experimental hepatic amebiasis. An ultras- tructural study. Am J Pathol 1988; 130: 112 –119.
9. Sepúlveda B, Martínez-Palomo A. Immunology of amebiasis by Entamoeba histolytica. In Cohen S, Warren K (eds): Immunology of Parasitic Diseases. Oxford, Blackwell Scientific Publications, 1982: 170
–191.
10. Eckmann L, Reed SL, Smith JR, Kagnoff MF. En- tamoeba histolytica trophozoites induce an inflam- matory cytokine response by cultured human cells through the paracrine action of cytolytically relea- sed interleukin-1 alpha. J Clin Invest 1995; 96(3): 1269–1279.
11. Seguin R, Mann BJ, Keller K, Chadee K. The tumor necro-sis factor alpha-stimulating region of alacto- se-inhibitable lectin of Entamoeba histolytica ac- tivates gamma interferon-primed macrophages for amebicidal activity mediated by nitric oxide. Infect Immun 1997; 65(7): 2522–2527.
12. Sharma M, Bhasin D, Vohra H. Differential induc- tion of immunoregulatory circuits of phagocytic cells by Gal ⁄ Gal NAc lectin from pathogenic and non- pathogenic Entamoeba. Clin Immunol 2008; 28(5): 542–557
13. Sharma M, Vohra H, Bhasin D. Enhanced pro-in- flammatory chemokine ⁄ cytokine response triggered by pathogenic Entamoeba histolytica: basis of inva- sive disease. Parasitology 2005; 131(Pt 6): 783–796.
14. Sierra-Puente RE, Campos-Rodriguez R, Jarillo-Luna RA, et al. Expression of immune modulator cytokines in human fulminant amoebic colitis. Parasite Immu- nol 2009; 31(7): 384– 391.
15. Kretschmer RR, López-Osuna M. Effector mechanis- ms and immunity to amebas. In Kretschmer R (ed.): Amebiasis: Infection and Disease by E. Histolytica. Boca Raton, FL, CRC Press, 1990: 105 –122.
16. Murray JS. How the MCM selects Th1/Th2 immuni- ty. Immunol Today 1998; 19: 157 –163)
17. Seydel KB, Smith SJ, Stanley SL Jr. Innate immunity to amebic liver abscess is dependent on gamma inter- feron and nitric oxide in a murine model of disease. Infect Immun 2000; 68(1): 400–402.
18. Seydel KB, Zhang T, Stanley SL Jr. Neutrophils play a critical role in early resistance to amebic liver absces- ses in severe combined immunodeficient mice. Infect Immun 1997; 65(9): 3951–3953
19. Seydel KB, Li E, Swanson PE , Stanley SL Jr. Human intes-tinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mou- se-human intestinal xeno-graft model of amebiasis. Infect Immun 1997; 65(5): 1631– 1639.
20. Bansal D, Sehgal R, Charla Y, Malla N, Majan C. Cytokine mRNA expressions in symptomatic vs. asymptomatic amoebiasis patients. Parasite Immunol 2005; 27: 37 – 43.
21. Salata RA, Murray HW, Rubin BY, Ravdin JI. The role of gamma interferon in the generation of human macrophages cytotoxic for Entamoeba histolytica tro- phozoites. Am J Trop Med Hyg 1987; 37(1): 72–78.
22. Lotter J, Gaworski I, Tannich E. Sexual dimorphism in the control of amebic liver abscess in a mouse mo- del of disease. Infect Immun 2006; 74: 118 –124.
23. Seguin R, Mann BJ, Keller K, Chadee K. The tumor necro-sis factor alpha- stimulating region of galac- tose-inhibitable lectin of Entamoeba histolytica ac- tivates gamma interferon-primed macrophages for amebicidal activity mediated by nitric oxide. Infect Immun 1997; 65(7): 2522–2527.
24. Ivory CP, Prystajecky M, Jobin C, Chadee K. Toll-li- ke receptor 9-dependent macrophage activation by Entamoeba histolytica DNA. Infect Immun 2008; 76(1): 289–297.
25. Eckmann L, Reed SL, Smith JR, Kagnoff MF. En- tamoeba histolytica trophozoites induce an inflam- matory cytokine response by cultured human cells through the paracrine action of cytolytically relea- sed interleukin-1 alpha. J Clin Invest 1995; 96(3): 1269–1279.
26. J. Pacheco-Yépez, J. M. Galván-Moroyoqui, I. Meza,
V. Tsutsumi & M. Shibayama. Expression of cytokines and their regulation during amoebic liver abscess development. Parasite Immunology, 2011, 33, 56–64.
27. Blazquez S, Rigothier MC, Huerre M, Guillen N. Initiation of inflammation and cell death during liver abscess formation by Entamoeba histolytica depends on activity of the galac-tose ⁄ N-acetyl-D-galactosa- mine lectin. Int J Parasitol 2007; 37(3–4): 425–433.
28. Bracha R, Nuchamowitz Y, Leippe M, Mirelman D. Anti-sense inhibition of amoebapore expression in Entamoeba histolytica causes a decrease in amoebic virulence. Mol Microbiol 1999; 34(3): 463–472
29. Nakada-Tsukui K, Saito-Nakano Y, Ali V, Nozaki T. A retromer-like complex is a novel Rab7 effector that is involved in the transport of the virulence factor cysteine protease in the enteric protozoan parasite Entamoeba histolytica. Mol Biol Cell 2005;16(11): 5294–5303.
30. Pacheco J, Shibayama M, Campos R, et al. In vitro and in vivo interaction of Entamoeba histolytica Gal⁄ GalNAc lectin with various target cells: an immu-nocytochemical analysis. Parasitol Int 2004; 53(1): 35–47.
31. Campbell D, Gaucher D, Chadee K. Serum from Entamoeba histolytica infected gerbils selectively suppresses T cell proliferation by inhibiting inter- leukin-2 production. J Infect Dis 1999; 179: 1495
–1501.
32. Schain DC, Salata RA, Ravdin JI. Human T-lympho- cyte proliferation, lymphokine production, and ame- bicidal activity elicited by the galactose-inhibitable adherence protein of Entamoeba histolytica. Infect Immun 1992; 60(5): 2143– 2146.
33. Hoebe K, Janssen Beutler B. The interface between innate and acquired immunity. Nat Immunol 2004; 10: 971– 974.
34. Kopf M, Gros G, Coyle A, Kosco-Vilbois M,; Brom- bacher F. Immune responses of IL-4, IL-5, IL-6- defi- cient mice. Immunol Rev 1995; 148: 45 – 69.
35. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lu- cian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64: 3231– 3235.
36. Ramsay AJ, Husband AJ, Ramshaw IA, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561– 563.
37. Fattori E, Cappelletti M, Costa P, et al. Defective in- flammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 1243 –1250.
38. Romani L, Mencacci A, Cenci E, et al. Impaired neu- trophil response and CD4 + T- helper cell-1 develo- pment in interleukin-6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345–1355.
39. Rincon M, Anguita J, Nakamura T, Fikrig E, Flave- ll M. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4 + T-cells. J Exp Med 1997; 185: 461– 469.
40. La Flamme AC,Pearce EJ. The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B-cell responses. J Immunol 1999; 162: 5829 –
5837
41. Yamamoto I, Yoshizaki K, Kishimoto T; Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878 – 4882.
42. Wang J, Homer RJ, Chen Q; Elias JA. Endogenous and exogenous IL-6 inhibits aeroallergen-induced Th2 inflammation. J Immunol 2000; 165: 4051– 4061.
43. Xing Z, Gauldie J, Cox G, et al. IL-6 is an anti-in- flammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311–320 31.
44. Tilg H, Trehu E, Atkins MB, Dinarello CA; Mier JW. Interleukin-6 (IL-6) as an anti inflammatory cyto- kine: induction of circulating IL-1 receptor antago- nist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113 – 118.
45. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Control of leukocyte infiltration during inflam- mation: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruit- ment. Immunity 2001; 14: 705– 714.
46. Barton BE, Jackson JV. Protective role of interleu- kin-6 in the lipopolysaccharide gAHActosamine septic shock model. Infect Immun 1993; 61: 1496
–1499.
47. Ulich TR, Yin S, Guo K, Yi ES, Remick D; del Casti- llo J. Intratracheal injection of endotoxin and cytoki- nes: interleukin-6 and transforming growth factor β inhibit acute inflammation. Am J Pathol 1991; 138: 1097 –1101.
48. Onogawa T. Local delivery of soluble interleukin-6 receptors to improve the outcome of α-toxin produ- cing Staphylococcus aureus infection in mice. Immu- nobiology 209: 651– 660.
49. Bekker C, Arellano J, Talamas P, Kretschmer R, Pe- rez-Rodriguez ME. Amebic lectin stimulation of lym- phocytes of Mexican Mestizos recovered from amebic abscess of the liver induces decreased production of IL5 and IL6. Arch of Med Res 2000; 31 (4 Suppl.): S96 – S97.
50. Bekker-Mendez VC, Perez-Castillo VL, Rico-Rosillo MG, et al. Downregulation of selected cytokines in amoebiasis. Arch Med Res 2006; 37: 556 – 558.
51. Bansal D, Sehgal R, Chawla Y, Malla N, Mahajan RC. Cytokine mRNA expressions in symptomatic vs. asymptomatic amoebiasis patients. Parasite Immunol 2005; 27(1–2): 37–43.
52. Campos-Rodriguez R, Gutierrez-Meza M, Jari- llo-Luna RA, Drago-Serrano ME, Abarca-Rojano E, Ventura-Juarez J, Cardenas-Jaramillo, LM, Pache- co-Yepez, J. 2016. A review of the proposed role of neutrophils in rodent amebic liver abscess models. Parasite. 23 (6).
53. Choi MH, Sajed D, Poole L, Hirata K, Herdman S, Torian BE, Reed SL. 2005. An unusual surface pe- roxiredoxin protects invasive Entamoeba histolytica from oxidant attack. Molecular and Biochemical Pa- rasitology, 143(1), 80–89.
54. Tseng CW, Liu GY. 2014. Expanding roles of neutro- phils in aging hosts. Current Opinion in Immunolo- gy, 29C, 43–48.
55. Cruz-Baquero A, Cárdenas Jarmillo LM, Gutié- rrez-Meza M, Jarillo-Luna RA, Campos-Rodriguez R, Rivera-Aguilar V, Milliar-García A, Pacheco-Ye- pez J. Differente behavior of myeloperoxidase in two rodent amoebic liver abscess models. Plos One. Aug 10;12(8). (2017)
56. Castañeda, J., Gómez, K., Corrales, L., Cortés, S. Perfil de resistencia a antibióticos en bacterias que presentan la enzima NDM-1 y sus mecanismos aso- ciados: una revisión sistemática. NOVA. 2016; 14 (26): 95-111
57. Ospino, K., Castilla, M., Sánchez, R. Resistencia microbiana desde una perspectiva metagenómica. NOVA. 2018; 16 (29): 91-100
58. Pinilla, G., Bautista, A., Cruz, C., Chavarro, B., Na- varrete, J., Muñoz, L., Gutiérrez, J. Determinación de factores de adhesión asociados a la formación de biopelícula en aislamientos clínicos de Staphylococ- cus aureus y Staphylococcus epidermidis. NOVA. 2017; 15 (27): 67 - 75
59. Boegemann M, Aydin AM, Bagrodia A , Krabbe LM . Prospects and progress of immunotherapy for bladder cancer. Expert Opin BiolTher. 2017 Nov;17(11):1417- 1431. doi: 10.1080/14712598.2017.1366445. Epub 2017 Aug 23.

Descargas

La descarga de datos todavía no está disponible.

Artículos más leídos del mismo autor/a